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Poxvirus challengeine model expressing the rhesus macaque (RM) Mamu-A⁎01 MHC allele to
characterize immune responses and vaccines based on antigens of importance to human disease processes.
Towards that goal, transgenic (Tg) mice expressing chimeric RM (α1 and α2 Mamu-A⁎01 domains) and
murine (α3, transmembrane, and cytoplasmic H-2Kb domains) MHC Class I molecules were derived by
transgenesis of the H-2KbDb double MHC Class I knockout strain. After immunization of Mamu-A⁎01/Kb Tg
mice with rVV-SIVGag–Pol, the mice generated CD8+ T-cell IFN-γ responses to several known Mamu-A⁎01
restricted epitopes from the SIV Gag and Pol antigen sequence. Fusion peptides of highly recognized CTL
epitopes from SIV Pol and Gag and a strong T-help epitope were shown to be immunogenic and capable of
limiting an rVV-SIVGag–Pol challenge. Mamu-A⁎01/Kb Tg mice provide a model system to study the Mamu-
A⁎01 restricted T-cell response for various infectious diseases which are applicable to a study in RM.
© 2009 Elsevier Inc. All rights reserved.IntroductionHomologues of the humanmajor histocompatibility complex (MHC)
Class I (Bontrop et al., 1995), Class II (Slierendregt et al., 1992) and TCR
genes (Levinson et al., 1992) can be identiﬁed in rhesus macaque (RM)
and are remarkably similar to human counterparts. The close evolu-
tionary similarity betweenRMandhumansmakes them suitable animal
models to study the immunology of human immunodeﬁciency virus
(HIV) infection using the RM infectious homologue simian immunode-
ﬁciency virus (SIV) (Letvin et al., 1983, 1984) and other examples of
prominent infectious disease models with clinical applications (Barry
et al., 2006; Belshe et al., 1977; Desrosiers et al., 1989; Felsenfeld and
Schmidt,1975; Polozov et al.,1978; Raengsakulrach et al., 1999; Rivailler
et al., 2004; Sun et al., 2006; Wang, 2001; Yang et al., 1999; Yue et al.,
2007; Zhu et al., 1997). Speciﬁcally, both SIV and HIV are primate
lentiviruses which use the CD4 protein as a primary receptor and
chemokine receptors as coreceptors for cell entry (Boyson et al., 1996;
Klatzmann et al., 1984). After infection with SIV, most RM develop a
disease similar to HIV-1-induced AIDS (King et al., 1990), consequentlyll rights reserved.SIV infection of the RM is currently considered thebest animalmodel for
HIV infection of humans. RMare considered thepre-clinical standard for
HIV/AIDS vaccine development utilizing SIV challenge.
Several vaccine studies in RM have suggested that strong immune
responses to SIV protect against the development of AIDS in some
monkeys (Daniel et al., 1985; Day et al., 2006; Lehner et al., 1996;
Mossman et al., 1996). CD8+ T cells contribute to this protective
immunity based on accumulated evidence implicating Tcell responses
in the control of HIV/SIV replication (Brodie et al., 1999; Charini et al.,
2001; Hirsch et al., 1994; Matano et al., 1998; Schmitz et al., 1999). The
Mamu-A⁎01 Class I MHC allele is present in about 25% of RM of Indian
origin (Knapp et al., 1997; Vogel et al., 1995). Tetramers for the single
Mamu-A⁎01-restricted cytotoxic T lymphocyte (CTL) epitope Gag-
CM9 (CTPYDINQM) have been developed to analyze Gag-speciﬁc CTL
in the peripheral blood of SIV infected RM (Allen et al., 1998; Charini
et al., 2001; Kuroda et al., 1998).
SIV disease progression was signiﬁcantly delayed in Mamu-A⁎01
positive RM infected with SIV compared to monkeys whom did not
express this allele (Evans et al., 1999, 2000; Muhl et al., 2002; Pal et al.,
2002; Zhang et al., 2002). The studies also showed that RM that express
the Class I Mamu-A⁎01 molecule control viremia after infection by a
chimeric lentivirus composed of elements from both HIV and SIV,
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(Mothe et al., 2003). This improved control of viral replication correlated
with the development of a high-frequency dominant epitope Gag-
speciﬁc CTL response following infection (Seamanet al., 2005). Similarly,
the Mamu B⁎17 alleles also has been associated with slower disease
progression in SIV-infected RM (Allen et al., 1998; Evans et al., 2000;
Loffredo et al., 2007, 2008). A comparable set of observations was more
recently made for RM with the B⁎08 allele (Loffredo et al., 2007, 2008).Fig. 1. (A) Scheme for generating H-2Kb promoter Mamu-A⁎01/Kb transgene construct. P1 a
the construction of the chimeric gene. The stippled boxes correspond to exons which enco
introns and the endogenous promoter segment is designated by a box containing an arrow in
the cloned MamuA⁎01MHC gene are shown as represented in the genome (ii), and their pos
transgenesis into the DKO mice (iii). (B) Stabilization of cell surface expression of Mamu-A
peptides LA9, LV10, GM10 and MI8. See Table 1 for amino acid sequences. After overnight c
added or no peptide for the control, with subsequent incubation for 4 h at 37 °C. Analysis wa
The GYKDGNEYI peptide represents an irrelevant peptide (control peptide).The term elite controllers (EC) has been coined to distinguish RMwhich
durablycontrol SIVviral load, andseveraldifferentMamualleles (Mamu-
A⁎02, B⁎08, B⁎17) have been implicated (Friedrich et al., 2007; Loffredo
et al., 2007). It is an important question whether the mechanisms for
control of SIV replication are synonymous with HIV-infected humans
also designated as EC and who are characterized by unique HLA alleles.
To begin to address some of these questions in an easily manipu-
latable model, we developed a transgenic mouse expressing thend P2 are sites of Mamu-A⁎01 speciﬁc primers. See Materials and methods for details of
de the TM and cytoplasmic (CT) domains of the H-2Kb gene (i). Clear boxes represent
dicating the direction of transcription (i). The leader peptide (LP),α1 andα2 domains of
ition between Nru I and Bam HI sites of the modiﬁed H-2Kb gene that was introduced by
⁎01/Kb in RMA-S cells with CM9 peptide or (C) four known Mamu-A⁎01 restricted SIV
ulture of Mamu-A⁎01/Kb-RMA-S cells at 26 °C, 10−5 M of the indicated peptides were
s initiated by staining with MAbW6/32 conjugated to FITC, followed by ﬂow cytometry.
Fig. 1 (continued).
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Immunization of the mice with rVV expressing SIV genes successfully
caused stimulation of CD8+ T cells recognizing previously known
Mamu A⁎01-restricted CTL epitopes that we quantiﬁed using
cytokine ﬂow cytometry. Mamu-A⁎01/Kb mice provides a simple
and inexpensive model that may allow further mechanistic insight
into EC status (Herberts et al., 2006; Loffredo et al., 2007, 2008).
Additional alleles could be used to generate other Tg mouse strains
that might inform on the mechanistic basis for suppression of SIV.
The similarity of outcome of SIV infection in EC RM and HIV infection
in EC humans with selected MHC alleles makes the study of the
biology and immunology of these alleles of great interest. A Tg mouse
model may improve understanding of the role of speciﬁc HLA or RM
alleles on infection outcome.
Results
Structure of Mamu-A*01/Kb transgene and expression in murine cells
The transgene encoding chimeric Mamu-A⁎01/Kb was con-
structed, as illustrated in Fig. 1A. It is comprised of the native H-2Kb
gene including the genomic promoter DNA sequence (Fig. 1A, i),
followed by the leader sequence through to the third intron derived
from Mamu-A⁎01 genomic DNA, replacing the corresponding murine
sequence (Fig. 1A, ii). The chimeric gene terminates with the α3
domain of the H-2Kb gene, followed by transmembrane (TM) and
cytoplasmic tail (CT) exons derived from the murine gene (Fig. 1A, iii).
To test if the chimeric Mamu-A⁎01/Kb protein has the capacity for cell
surface expression, the chimeric gene construct was introduced into
TAP-deﬁcient RMA-S cells using standard approaches described in
Materials and methods. These cells are deﬁcient in cell surface MHCClass I expression, because of the defect in endogenous peptide
generation that can be overcome by providing exogenous optimal
peptide motifs corresponding to MHC alleles carried by RMA-S cells
(Ljunggren et al., 1990). The results show that a high level of Mamu-
A⁎01/Kb complex formation is detected by incubation with epitope
CM9 (an optimal Mamu-A⁎01 motif peptide, see Table 1), but not an
irrelevant epitope in RMA-S transfectants (Fig. 1B, right panel), and
not in untransfected RMA-S cells (Fig. 1B, left panel). Four identiﬁed
Mamu-A⁎01 speciﬁc SIV epitopes: LA9, LV10, GM10 and MI8 (see
Table 1) were also evaluated for their ability to promote cell-surface
expression of the Mamu-A⁎01/Kb MHC protein at 37 °C (Fig. 1C). A
relatively high level expression ofMamu-A⁎01/Kbwas observed in the
presence of LA9 peptide, and to a lesser extent, expression of Mamu-
A⁎01/Kb was stabilized by incubation with GM10 and MI8 peptides.
However, LV10 peptide stabilized a low level of the expression of
Mamu-A⁎01/Kb. These results are evidence that the Mamu-A⁎01/Kb
chimeric proteinwas translated and processed correctly, and could be
brought to the cell surface in the presence of peptides that bound
unmodiﬁed Mamu-A⁎01 MHC molecules.
Expression of Mamu-A⁎01/Kb in H-2Kb/Db knockout mice
Transgene DNA was microinjected into a total of 230 fertilized eggs
from DKOmice, however only 17 pups were born and survived because
of the reduced viability of the eggs from the DKO strain (data not
shown). The Mamu-A⁎01 gene was detected in three founders by PCR
using Mamu-A⁎01 speciﬁc primers on tail DNA from newly weaned
mice (Fig. 2A). Tg mice were backcrossed with DKO mice to derive
Mamu-A⁎01 (heterozygous) animals for preliminary immunologic
testing and to derive stable homozygous lines of Tg mice. Freshly
prepared splenocytes were obtained from heterozygous Mamu-A⁎01/
Table 1
Summary properties of SIV-derived Mamu-A⁎01 peptides
SIV gene Peptide name Amino acid sequence Reference MFI % IFN-γ CD8+ T cells
Gag LA9 LAPVPIPFA Allen et al. (2001) 23.4 9.52
Gag CM9 CTPYDINQM Allen et al. (1998) 34.4 67.25
Gag LW9 LSPRTLNAW Allen et al. (2001) 1.72 7.81
Pol LV10 LGPHYTPKIV Allen et al. (2001) 1.58 4.02
Pol SV9 STPPLVRLV Egan et al. (1999) 45.8 10.1
Pol GM10 GSPAIFQYTM Allen et al. (2001) 9.06 2.51
Pol MI8 MTPAERLI Allen et al. (2001) 11.2 4.65
Seven previously deﬁned Mamu-A⁎01 restricted SIV Gag and Pol epitopes were tested for stabilization of cell surface expression of Mamu-A⁎01/Kb in RMA-S cells, and induction of
intracellular IFN-γ production in CD8+ T cells after IVS of rVV-SIVGag–Pol immunized Mamu-A⁎01/Kb Tg mice (N=2) for each peptide. Background binding to a control peptide was
subtracted for RMA-S assays, and the percentage of IFN-γ+ CD8+ Tcells from a mock-stimulated culture was subtracted from all ICC assay results. The mean ﬂuorescence intensity (MFI)
andpercentage of intracellular IFN-γpositiveofCD8+Tcellswere determinedbyﬂowcytometryusing a FACS-Canto™ (BDIS, San Jose, CA). Results shownare anaverage ofN=2micewith
b25% standard error from the mean.
19J. Li et al. / Virology 387 (2009) 16–28Kb Tg mice, though only weak levels of expression of Mamu-A⁎01
molecules was documented by staining usingMAbW6/32, followed by
ﬂow cytometry (Fig. 2B, right). Under the same conditions, no signal
could be detected on spleen cells from parental DKOmice (Fig. 2B, left).
Since the Mamu-A⁎01/Kb chimeric gene is under the control of H-2Kb
promoter, we treated Tg mouse splenocytes with murine IFN-γ for 16 h
to activate the promoter (Israel et al., 1986). Consequently the surface
expression of Mamu-A⁎01/Kb increased dramatically in cells from
Mamu-A⁎01/Kb Tg mice (Fig. 2B, right). IFN-γ also enhanced the
background, which was detected by MAbW6/32 in cells from parental
DKO mice, but the elevated level was much lower than in cells from
Mamu-A⁎01/Kb Tg mice (Fig. 2B, left).
Derivation of rVV and proteolytic processing of SIV Gag–Pol
antigen cassette
The central goal of this mouse derivationwas to generate a model to
evaluate vaccines that would be applicable for testing in RM. As a ﬁrstFig. 2. (A) Detection of Mamu-A⁎01 DNA in tail samples from 13 Tg mice by PCR. Cont symbo
ladder molecular size marker. (B) Detection of cell surface expression of Mamu-A⁎01/Kb M
(right) mice were stained with FITC-conjugated MAb W6/32 followed by ﬂow cytometry.
expression levels.step, we evaluated the immunogenicity and processing of an rVV
expressing full-length SIVGag–Pol antigens in Mamu-A⁎01/Kb Tg mice
and the parental DKO strain of which they were derived (Fig. 3A). The
rVV-SIVGag–Pol was derived by homologous recombination and the
expression of the SIV Gag proteinwas veriﬁed by Western Blot. SIV Gag
protein is expressed as a 58-kDa polyprotein precursor (p58), which is
cleaved in a sequential manner by the SIV-encoded viral protease into
matrix, capsid (p27), and nucleocapsid proteins. Western Blot of lysates
prepared fromHuTK− cells infectedwith rVV-SIVGag–Pol byusing anti-
p27 antibodyconﬁrmed theSIVGagproteinwasexpressed and correctly
proteolytically processed (Fig. 3B).
CD8+ T cell response induced by Mamu-A⁎01 restricted epitopes in
Mamu-A⁎01/Kb Tg mice
Mamu-A⁎01/Kb Tg (N=2) and parental DKO mice (N=2) were
infected with rVV-SIVGag–Pol by i.p. injection for two weeks. Spleens
were removed, and cell suspensions were incubated for 7 days withlizes control transgene Mamu-A⁎01/Kb plasmid DNA template. M represents 1 kb DNA
HC antigen in spleen cells. Splenocytes from DKO (left) mice and Mamu-A⁎01/Kb Tg
Splenocytes were also treated with 15 ng/ml IFN-γ for 16 h to enhance MHC antigen
Fig. 3. (A) Schematic map of plasmid transfer vector pSC11-GFP-SIVGag–Pol. It contains two ﬂanking regions; TK(L) and TK(R) which are homologous to the VV-TK gene, the screen
marker gene GFP under the control of the VV promoter P11, and the SIVGag–Pol gene from SIVmac239 under control of VV promoter P7.5. rVV-SIVGag–Pol was generated by
transfecting pSC11-GFP-SIVGagPol into VV-infected Hu TK− cells to promote homologous recombination. (B) Western Blot detection of SIV Gag protein in rVV-SIVGag–Pol infected
cells. Lysates from rVV-SIVGag–Pol and wild type VV infected Hu TK− cells were separated on SDS-PAGE and detected with anti-P27MAb, followed by an HRP conjugated anti-mouse
secondary antibody contained in the ECL™ kit (GE Healthcare). (C) ICC of IFN-γ production in CD8+ T lymphocytes fromDKOmice (ii) andMamu-A⁎01/Kb Tgmice (iv) after IVS and
restimulationwith CM9 peptide. Plots (i) and (iii) are negative controls without CM9 peptide restimulation. (D) Detection of IFN-γ production in CD8+ T lymphocytes after IVS with
four known Mamu-A⁎01 speciﬁc SIV peptides: LA9 (i), GM10 (ii), LV10 (iii) and MI8 (iv). In C and D, IVS followed by overnight peptide restimulation was performed according to
Materials and methods followed by staining with anti-CD8 and anti-IFN-γ antibodies, and analyzed by ﬂow cytometry.
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Fig. 3 (continued).
21J. Li et al. / Virology 387 (2009) 16–28peptide CM9 (Table 1), using peptide-pulsed RMA-S/Mamu-A⁎01/Kb as
APC. Analysis of cultured splenocytes by ﬂow cytometry to detect
intracellular stainingof IFN-γwasperformed. Remarkably, the immuno-
dominant CM9 epitope stimulated 67.25% of CD8+ T lymphocytes to
produce IFN-γ from the splenocyte culture, shownasone example of the
Mamu-A⁎01/Kb Tg mice we immunized, while only background levels
were detected in the absence of the SIV epitope restimulation (Fig. 3C, iii
and iv). As expected, splenocytes from parental DKO mice showed
minimal recognition of the CM9 epitope (Fig. 3C, i and ii).
Existing Mamu-A⁎01-restricted epitopes are recognized after
rVV-SIVGag–Pol infection
We further investigated the breadth of epitope recognition after
rVV-SIVGag–Pol immunization of Mamu-A⁎01/Kb Tg mice, by exa-
mining the immune recognition of 4 previously characterized Mamu-
A⁎01 restricted epitopes (LA9, LV10, GM10 and MI8, Table 1) after IVS
with these 4 peptides. All of the peptideswhichwere found to stabilize
Mamu-A⁎01 surface staining in RMA-S/Mamu-A⁎01/Kb cells (Fig. 1C)
also induced CD8+T lymphocytes to produce IFN-γ (Fig. 3D). LA9which
stabilized a high level of the Mamu-A⁎01 surface staining in RMA-S/
Mamu-A⁎01/Kb cells (Fig. 1C), also induced a high level of IFN-γ
producing CD8+ T lymphocytes (9.52%) in Mamu-A⁎01/Kb splenocyte
cultures (Fig. 3D, i). LV10 which minimally stabilized Mamu-A⁎01
surface staining in RMA-S/Mamu-A⁎01/Kb cells also induced a similar
level of IFN-γ production as the other two peptides GM10 and MI8
whichmoderately stabilizedMamu-A⁎01 surface staining. These results
are supportingevidence that theMamu-A⁎01/Kb Tgmice contain a Tcell
repertoire that faithfully reproduces T cell recognition comparable toMamu-A⁎01 RM, and will be a useful tool for the evaluation of virus-
speciﬁc, Mamu-A⁎01 restricted T cell response.
Screening of SIV Gag peptide library and identiﬁcation of CD8+ T cell
epitopes in Mamu-A⁎01/Kb Tg mice
We tested whether Mamu-A⁎01/Kb Tg mice could be used to
distinguish and ﬁnely map Mamu-A⁎01 restricted epitopes to the
level of minimal peptides starting with a library of 125 15-mer
peptides overlapping by 11 amino acids that encompasses the entire
SIVmac239 Gag amino acid sequence. Two Mamu-A⁎01/Kb Tg mice
(Tg line 4) which were previously immunized with rVV-SIVGag–Pol
were used for this approach. Immune splenocytes were stimulated
with the complete library or 8 peptide subpools, each containing 16
component peptides from the whole library (Fig. 4A). T cell
responses induced against each pool of peptides were analyzed by
ICC for IFN-γ. Peptide pool 33–48 reproducibly induced high
frequencies of IFN-γ expressing CD8+ T cells (46% and 69%), while
peptide pools 81–96 and 97–112 also induced moderate levels of
IFN-γ expressing CD8+ T cells ranging from 5.45% to 31.8% (Fig. 4A).
Each of the three responding pools was further analyzed by testing
each of the component peptides individually. Peptides 45 and 46
containing the CM9 epitope sequence (Table 1) induced IFN-γ
expressing T cells very efﬁciently (81.5% and 84.5%, Fig. 4B), similar
to the levels stimulated by the minimal 9-mer CM9 epitope (Fig. 3C).
In addition, peptides 38 and 39 also induced IFN-γ producing T cells,
although at a lower level (16.2% and 9.32%). Peptide 38 contains a
previously identiﬁed Mamu-A⁎01 restricted epitope LW9 (Table 1).
In addition, as shown in Fig. 4C, both peptides 92 and 93 induced a
Fig. 4. Mapping Mamu-A⁎01 restricted epitopes of SIV Gag by intracellular IFN-γ
staining in CD8+ Tcells after IVS. Splenocytes from rVV-SIVGag–Pol immunized Mamu-
A⁎01/Kb Tg mice were subjected to IVS with 8 SIV Gag peptide subpools or the full-
length peptide library. (A) Reactive peptide pools were deconvoluted by testing
individual SIV Gag peptides 33 to 48 (B), and 81 to 96 (C).
Fig. 5. Mapping Mamu-A⁎01 restricted epitopes of SIV Pol by intracellular IFN-γ
staining in CD8+ Tcells after IVS. Splenocytes from rVV-SIVGag–Pol immunized Mamu-
A⁎01/Kb Tg mice were subjected to IVS in similar conditions as described in the legend
to Fig. 4 with 11 SIV Pol peptide subpools (A). Individual SIV Pol peptide pools were
evaluated between 145 to 168 (B).
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16.8%). These two 15-mer peptides contain an identiﬁed Mamu-A⁎01
restricted epitope, LA9 (Table 1).
Screening of SIV Pol peptide library and identiﬁcation of CD8+ T
cell epitopes
In SIV or SHIV infected RM, Pol speciﬁc CTL responses were
observed at low frequencies (Allen et al., 2001; Egan et al., 1999).
These observations led us to investigate the processing of the Pol
protein sequence in Mamu-A⁎01/Kb Tg mice. In rVV-SIVGag–Pol
infected lysates, SIV Gag polyprotein was proteolytically cleavedprecisely according to expected MW, suggesting that the protease
encoded in the Pol sequence is active, and that SIV Pol proteinwas also
expressed (Fig. 3B). IVS was conducted on splenocytes from two rVV-
SIVGag–Pol immunized Mamu-A⁎01/Kb Tg mice with eleven peptide
subpools, each consisting of 24 15-mer peptides spanning the entire
SIVmac239 Pol protein. Seven days later, the IVS-stimulated spleno-
cytes were analyzed for expression of the intracellular cytokine IFN-γ
in CD8+ T cells (Fig. 5A). A moderate level of IFN-γ expressing CD8+ T
cells were induced by peptide pool 145–168 (7.7% and 16.6%). In
addition, low levels of IFN-γ expressing CD8+ T cells were reprodu-
cibly induced by peptide pools 1–24, 25–48, 49–72, 169–192 and 217–
240 with frequencies ranging from 2.5% to 3.9%. We assessed
individual component peptides from pool 145–168 for their ability
to induce IFN-γ expressing CD8+ T cells (Fig. 5B). We selected pool
145–168 for further analysis because it induced the highest level of
IFN-γ producing CD8+ Tcells among all the 11 subpools. Two peptides
among the 24 separately evaluated from pool 145–168 showed equally
high levels of response using the ICC assay (Fig. 5B). Both peptides 156
and 157 contain the known Mamu-A⁎01 restricted epitope SV9 were
found to induce IFN-γ producing Tcells at equivalent levels (12.2% and
12.3%, Fig. 5B) and (Table 1).
Immunization with fusion peptide vaccines
Based on our previous success with the PADRE:CTL fusion peptide
vaccine model for HIV vaccines in HLA A2/Kb mice (Daftarian et al.,
2003), we synthesized an analogous structure for 3 different CTL
epitopes from SIV Gag and Pol shown in Table 2 (MI8, LW9, CM9). The
Table 2
Nomenclature, molecular weight and amino acid sequence of synthetic minimal CTL and TH epitopes and epitope fusion peptides
Compound Name aMW (kDa) Sequence
Pan DR binding epitope (Alexander et al., 1994) PADRE 1.354 AKbXVAAWTLKAAA
PADRE:SIVGag181–189 fusion PADRE:CM9 2.419 AKbXVAAWTLKAAACTPYDINQM
PADRE:SIVGag149–157 fusion PADRE:LW9 2.393 AKbXVAAWTLKAAALSPRTLNAW
PADRE:SIVPol961–969 fusion PADRE:MI8 2.266 AKbXVAAWTLKAAAMTPAERLI
CpG-ODN #7909 (Hartmann et al., 2000) CpG-Human 7.900 5′ TCGTCGTTTTGTCGTTTTGTCGTT 3′
The sequences are shown for the components and ﬁnal products that were used in the fusion peptide immunization. The sequence and names of the CTL epitopes can be found in
Table 1. Details of fusion peptides and structure can be found in prior publications (Daftarian et al., 2005;La Rosa et al., 2002). Active CpG motif underlined.
a MW = molecular weight conﬁrmed by mass spectroscopy.
b X = cyclohexyl-alanine.
23J. Li et al. / Virology 387 (2009) 16–28vaccination approach we employed for the studies shown in Fig. 6
combined 100 nmol fusion peptide and 25 μg CPG 7909 DNA
(Hartmann et al., 2000), administered s.c., similar to our published
studies for HIV-speciﬁc fusion peptides (Daftarian et al., 2003). Shown
are results from two identically immunized mice for each peptide
fusion, analyzed for IFN-γ producing T-cells using ICC (Fig. 6A). ICC
evaluations of splenocytes were conductedwith a non-speciﬁc control
peptide (grey bars) and the CTL epitope that is part of the fusion
peptide (black bars) for each fusion peptide that was studied. Of the
three CTL epitopes fused to the PADRE T-help peptide, the MI8
octamer was recognized most inefﬁciently after rVV-SIVGag–Pol
infection, but its fusion peptide was the best at eliciting antigen-
speciﬁc CD8+ T cells after immunization (Table 1 and Fig. 6A). The
LW9 nonamer was recognized with intermediate intensity, but its
fusion peptide was poorly immunogenic, whereas the CM9 nonamer
that was efﬁciently recognized after rVV-SIVGag–Pol infection also
elicited strong immunogenicity as a fusion peptide (Table 1 and Fig.
6A). Interestingly, the MI8 fusion peptide immunized without CpG
7909, showed an average of only 8.0% IFN-γ+ CD8+ T-cells in Mamu-
A⁎01 Tg mice (N=2), a N90% reduction from the immunization
containing CPG 7909 DNA (Fig. 6A).Fig. 6. Immunogenicity (A) and challenge studies (B) conducted with fusion peptide immu
+25 μg CPG 7909 DNA one time, and were sacriﬁced after 14 days for processing of splenoc
using CTL epitope encoded by fusion peptide (ﬁlled bars) or without exogenous peptide (gre
axis) were immunized with indicated amounts of fusion peptides +25 μg CPG 7909 DNA twi
were administered i.p. to immunized mice, as indicated in the legend above each data se
incubating with monolayers of CV-1 cells as described in Materials and methods. Plaques we
Dotted line indicates the limit of detection of VV plaques using the assay. P-values (2-sided) w
shown as one (Pb0.04) or two asterisks (Pb0.008). Standard error of the mean is shown
members of a group are represented by a single ﬁlled circle without error bars on the dotteChallenge with rVV-SIVGag–Pol
The MI8, LW9, and CM9 fusion peptides represent a large range of
immunogenicities. All 3 fusion peptides were administered to Mamu-
A⁎01/Kb Tg mice as a series of two immunizations that were spaced
two weeks apart, conducted as a limited dose titration between 1 and
100 nmol plus 25 μg of CpG 7909 ODN. Similar to the studies of
Berzofsky and collaborators, fusion peptides were introduced s.c. and
i.p. for both immunizations (Ahlers et al., 2001). Seven days after the
second immunization, immunized mice and a control unimmunized
litter-mate were i.p. administered 10 million infectious units (pfu) of
rVV-SIVGag–Pol or rVV-GFP. Five days later, ovaries were removed and
lysates were prepared, and stored in aliquots at−80 °C. Infection was
carried by a series of dilutions of the ovary lysate on CV-1 cell
monolayers for a period of 18 h by standard approaches. Results with
accompanying P-values are presented in Fig. 6B. Plaques were counted
by immunostain using a monoclonal antibody to VV as a primary, and
an HRP-conjugate as secondary (Wang et al., 2008). The left (L) and
right (R) ovaries were separately analyzed, but results of both ovaries
were consistent for both immunized and unimmunized mice. At the
lowest dilution tested of 103 of the ovary lysate from PADRE:MI8-nized Tg mice. (A) Tg mice (N=2) were immunized with 100 nmol of fusion peptides
ytes for ICC studies. ICC assays were carried out as described in Materials and methods
y bars). (B) Tg mice (number of mice indicated in parentheses for each group on the x-
ce as described in Materials and methods. Seven days later, rVV-SIVGag–Pol or rVV-GFP
ries. Five days later, mice were sacriﬁced, ovary lysates prepared, and diluted before
re visualized using immunostain to VV antigens as described in Materials and methods.
ere determined using theWilcoxon rank-sum test, and values which are signiﬁcant are
as horizontal bars, with means indicated as ﬁlled circles. Undetectable plaques in all
d line signifying the minimal detection limit.
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made of ovaries from rVV-SIVGag–Pol challenged mice (N=8). In
addition, PADRE:CM9 (10 nmol) immunized mice (N=5) also
showed no evidence of viral plaques at 103 dilution of the ovary
lysate, similar to the PADRE:MI8 immunized mice. However, the dose
titration down to 1 nmol fusion peptide was only partially effective at
controlling rVV-SIVGag–Pol infection for both MI8 (N=8) and CM9
(N=5) fusion peptides. The weakly immunogenic PADRE:LW9
(N=6) immunized mice (100 nmol) only gave partial protection to
challenge with rVV-SIVGag–Pol, similar to mice immunized with
1 nmol of either MI8 or CM9 fusion peptides. As expected, non-
immunized mice had substantial visible plaques at 107–108 dilutions
of the ovary lysates from either challenge virus (rVV-GFP (N=5) or
rVV-SIVGag–Pol (N=5), Fig. 6B). These results are informative for
exploring immunization strategies in RM.
Discussion
Mamu-A⁎01/Kb Tg derived from DKO mice were successfully
generated and employed to investigate recognition of Mamu-A⁎01
restricted epitopes produced by a model rVV-SIV. We constructed the
Mamu-A⁎01 transgene based on results of previous studies that
showed increased immunologic function of chimeric MHC molecules
composed of α1α2 domains from human HLA and H-2Kb α3 from
mouse (Kalinke et al., 1990; Vitiello et al., 1991). This strategy was
used to enable TCR-CDR3 and MHC-α1α2 interactions to more
efﬁciently activate T cells based on Mamu-A⁎01 restricted peptide
speciﬁcity. Complex stability between CD8+ T cells and professional
APC was enhanced by the interaction of endogenous murine CD8
molecules with the H-2Kb α3 mouse partner as a means to stabilize
the tripartite complex (Vitiello et al., 1991). The ﬁrst construct we
developed was composed of the promoter and three ﬁrst exons of
Mamu-A⁎01, and the α3, transmembrane and cytoplasmic domains
from H-2Kb genomic DNA (Fig. 1A and not shown). Following
transfection into murine ﬁbroblast NIH3T3 cells, the cell surface
expression of Mamu-A⁎01/Kb monochains was detected by indirect
immunoﬂuorescence. However, the cell surface expression of Mamu-
A⁎01/Kbwasminimal (data not shown).We attempted to improve the
transcriptional efﬁciency in mouse by replacing the Mamu-A⁎01
promoter with the H-2Kb promoter (Fig. 1A). This substitution proved
successful, because of improved surface expression that could be
dramatically enhanced by treatment of splenocytes derived from
Mamu-A⁎01/Kb Tg mice with murine IFN-γ (Fig. 2). This is the ﬁrst
example of aMamuMHC Tgmousewhichmay serve as a paradigm for
construction of other Mamu Class I allele strains.
We were concerned that differences in TAP speciﬁcity of RM and
murine Class I MHC would reduce the efﬁciency of endogenous
murine antigen-processing, resulting in reduced levels of peptide-
loaded and surface expressed Mamu A⁎01 MHC molecules. The
reduction of surface Mamu A⁎01, might negatively impact the
frequency and antigen speciﬁcity of the Mamu A⁎01-restricted
peripheral T cell repertoire in the Mamu-A⁎01/Kb Tg mice, rendering
them not useful for RM-speciﬁc vaccine studies. Others have found
that human β2-microglobulin (β2m) introduced into Tg mice by
covalent linkage to the N-terminus of the transgenic Class I heavy
chain constructed analogously, increased the cell surface expression of
the chimeric molecule in RMA cells (Pascolo et al., 1997). However, we
demonstrated that a relatively high level of Mamu-A⁎01/Kb expres-
sion could be stabilized by exogenous peptides in TAP-deﬁcient mouse
RMA-S lymphoma cells expressing Mamu-A⁎01/Kb without introdu-
cing covalently added human or RM β2m. Consistent with previous
reports describing HHD Tg mice derived from H-2Db β2m knockout
mice, the expression of Mamu-A⁎01/Kb molecules on T and B
peripheral cells was low(Pascolo et al., 1997). Nevertheless, our
results showed efﬁcient usage of the Mamu-A⁎01/Kb monochain to
generate a potent immune response induced by CD8+ T lymphocytes.Once homozygous animals are isolated, greater levels of CD8+ T
lymphocytes may be observed. Similar to the case of HHD Tg mice, the
expression of Mamu-A⁎01/Kb partially restores to normal levels, the
low levels of CD8+ T lymphocytes found in the periphery before
immunization or viral infection, potentially because of defective
positive selection in the absence of a classical MHC Class I gene in the
DKO mice (data not shown). Our results suggest that Mamu-A⁎01/Kb
monochain is able to replace the missing endogenous Kb or Db MHC
molecules to stabilize CD8 surface expression on circulating T
lymphocytes in the Tg mice.
We examined the usefulness of the Mamu-A⁎01/Kb mice to aid in
RM-speciﬁc CTL epitope identiﬁcation. Our strategy was to immunize
Mamu-A⁎01/Kb Tg mice with rVV-SIVGag–Pol that we constructed
from SIV genomic sequence containing plasmid DNA. CD8+ T cell
reactivity was screened using overlapping 15-mer peptide libraries
spanning SIV Gag and Pol proteins. Four CTL epitopes located within
the SIV Gag protein were identiﬁed. Among them, the previously
characterized CM9 peptide, and two other epitopes called LA9 and
LW9 (Allen et al., 2001) were identiﬁed, because they stimulated IFN-
γ expression in splenic CD8+ T cells. A previously described epitope
located within SIV Pol, SV9 (Egan et al., 1999) was also identiﬁed.
Although the Mamu-A⁎01/Kb Tg mice showed dramatic CD8+ T cell
responses to SIV immunodominant epitope CM9, they also recog-
nized a broad distribution of epitopes in SIV Gag and Pol proteins.
Both high (CM9) and moderate-low (LA9, LW9, SV9, LV10, GM10 and
MI8, Table 1) afﬁnity peptides elicited immunologic recognition in
Mamu-A⁎01/Kb Tg mice. The immunogenicity of the Mamu-A⁎01
restricted peptides identiﬁed through rVV infection and peptide
library screening suggests that the CD8+ T cell repertoire in the
Mamu-A⁎01/Kb Tg mice faithfully represents at least a portion of the
RM T cell repertoire. We also identiﬁed and ﬁne mapped two novel
Mamu-A⁎01-restricted CTL epitopes (data not shown): the SIV Gag-
derived epitope RW9 (RAPRRQGCW) and Pol-derived epitope NE8
(NFPIAKVE). To conﬁrm and further characterize these two newly
deﬁned epitopes with respect to their stage of appearance after SIV
infection, we will infect Mamu-A⁎01 positive RM with SIV and
enumerate antigen-speciﬁc CTL response in infected animals.
Tg mice expressing full length HLA Class I molecules were the ﬁrst
examples used to study HLA class I restricted CTL responses (Arnold
and Hammerling, 1991). Either through virus infection or allo-
stimulation by other HLA Class I alleles, these mice preferentially or
exclusively developed H-2-restricted CD8+ T cell responses, rather
than the desired HLA-restricted T cell responses (Barra et al., 1989;
Engelhard et al., 1991; La Rosa et al., 2001). Consequently, H-2Db and
β2m knockout mice expressing the HHD chimeric Class I molecule
were derived to force the CD8+ T cell repertoire to be educated by Tg
HLA Class I molecules (Pascolo et al., 1997). As a result, virus infection
of these Tg mice generated predominantly HLA-A2.1-restricted CD8+
T cell responses against inﬂuenza A and vaccinia viruses as
representative examples (Pascolo et al., 1997). We sought to simplify
and speed up the process of deriving a Tg Class I strain in the DKO
background. The process for deriving HHDmice required several time-
consuming steps, and we sought to reduce the process to a single step.
By doing so, it reduced the number of additional crosses to just one
that would be needed to generate homozygotes. This work represents
the ﬁrst example of a new Tg mouse strain derived by direct
transgenesis of a DKO strain. If we can improve the viability of the
eggs from the DKOmice during microinjection, it may be the best way
to generate Tg mice for other primate and human MHC Class I alleles.
There are many areas of study where these mice will prove useful.
Recently, we developed a vaccine consisting of rhesus cytomegalo-
virus (RhCMV) pp65, gB and IE1 expressed via modiﬁed vaccinia
Ankara (MVA), and evaluated it in RM, including some which are
Mamu-A⁎01 positive (Yue et al., 2008). Rhesus pp65 and IE1-speciﬁc
cellular immune responses were detected. To track the evolution of
these cellular immune responses using tetramers, especially in CMV-
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identiﬁed. The Mamu-A⁎01/Kb Tg mice, represent a facile system to
preliminarily identify potential CTL epitopes that can be later veriﬁed
in the Mamu A⁎01 RM. Identiﬁed epitopes would allow detailed
studies including those with tetramers to determine avidity and other
functional parameters (Egan et al., 1999). While we found no effect on
speciﬁcity of epitope detection, all of our studies utilized an
intermediate step of IVS to amplify the epitope-speciﬁc splenocyte
populations prior to conducting ICC. Our approach of employing IVS
when using transgenic mice is consistent with other studies from a
variety of laboratories (Pascolo et al., 1997; Vitiello et al., 1997). While
not optimal, the fact that protection studies correlatewith the levels of
immunogenicity measured in Fig. 6A suggests minimal disruption of
functional properties to distort the good correlation with the
challenge results (Fig. 6B).
CTL epitopes can be quickly identiﬁed using the mice, and veriﬁed
using appropriately infected RMwithMamu-A⁎01 allele. Another area
of investigation that will beneﬁt is the testing of vaccine concepts in
the relatively inexpensive Tg mice prior to evaluation in the costly RM
model. Since all HIV vaccine concepts must pass a macaque feasibility
test, using SIV or SHIV as a challenge virus, we envision preliminary
testing in this mouse model. Viruses, peptides, or DNA products that
elicit T cell response could be ﬁrst tested for immunogenicity in mice
prior to advanced testing in monkeys. Epitope based vaccines are
candidates for preliminary evaluation in mice prior to monkey testing,
including constructs similar to what we developed for HIV (Daftarian
et al., 2005). Our preliminary investigation of 3 Mamu-A⁎01 epitopes
incorporated into fusion peptide vaccines was informative, since the
immunogenicity characteristics of CTL epitopes processed from rVV-
SIVGag–Pol differed from the ranking of immunogenicity of the
peptide fusion vaccines. Whether the immunogenicity ranking
predicted by the mice is also similar in RM needs to be evaluated in
a separate study. The results of the challenge study reassured and
followed the results of the immunogenicity ranking, as LW9 fusion
peptide performed poorly in both tests. In contrast, the MI8 and CM9
fusion peptides performed well in both immunogenicity and chal-
lenge tests. Many other antigens from pathogens that infect RM could
be intensively studied immunologically in these mice to rapidly
identify epitopes that could be used to study disease pathogenesis or
vaccine strategies in the more costly primate model.
Materials and methods
Media, cell lines and mice
Continuously growing cell lines were maintained in RPMI 1640
(Cellgro, Herndon, CA) containing 10% FBS (Omega, Tarzana, CA), 4 mM
L-glutamine (GIBCO, Rockville, MD), 0.1 mM 2-mercaptoethanol, and
100U/mlpenicillin and100 μg/ml streptomycin (GIBCO). 2×107RMA-S
cells (Ljunggren et al., 1990) (transporter associated with antigen
presentation [TAP] negative, a kind gift from Dr. Martin Kast, USC Keck
School of Medicine) in 0.5 ml of PBS were electroporated with 15 μg of
linearized pH2KbMamu-A⁎01α1α2 DNA at 250 V and 2000 μF using a
BTX ECM 600 Electroporation System (BTX, San Diego, USA). After 24 h,
cells were transferred in selective medium containing 1.0 mg/ml G418
(Invitrogen, Carlsbard, CA) and cloned by limiting dilution in 96 well
plates. Neomycin-resistant stable clones expressing theMamu-A⁎01/Kb
gene were identiﬁed by PCR using the Mamu-A⁎01 speciﬁc primers 5-
GACAGCGACGCCGCGAGCCAA-3 and 5-CGCTGCAGCGTCTCCTTCCCC-3.
These cells were expanded in the absence of G418 selection, but were
periodically examined for expression of Mamu-A⁎01/Kb protein by
indirect immunoﬂuorescence using ﬂuorescein isothiocyanate (FITC)-
conjugated W6/32 MAb (Maziarz et al., 1986) (eBioscience, San Diego,
USA). Cells were evaluated by incubation overnight at 26 °C with a
Mamu-A⁎01 speciﬁc peptide and subsequent at 37 °C, followed by ﬂow
cytometry analysis. C57BL/6 H-2Kb/Db knockout (DKO) mice wereobtained from the Institute Pasteur (Paris, France) through an agree-
ment with NIAID and Taconic Laboratories (Germantown, NY). Mice
used throughout this study were bred and maintained under standard
pathogen-free conditions in the American Association for Laboratory
Animal Care approved animal care facility at City of Hope.
Transgene construction
Genomic DNA was isolated from C57BL/6 mouse tails by using
DNAzol (Molecular Research Center Inc., Cincinnati, OH). 5-CGCGG-
ATCCTGTGCTGAGGGGACCAGC-3 and 5-ATTTGCGGCCGCGTCTG-
TCACCAAGTCCACTCCAGGC-3 primers were used to amplify a DNA
fragment which contains the H-2Kb α3, transmembrane and cyto-
plasmic domains. The 1.3 kb PCR product was cloned into BamH I–Not
I sites of vector pEGFP-N3 (Clontech, Palo Alto, CA). 5-CGCAT-
TAATGTCGACGGTCAGGGAGGGAGGGAGAGGGTC-3 and 5-
CCCAAGCTTGTCGGCGATTCGCGACTTCTGAG-3 primers were used to
amplify the H-2Kb promoter. The 1.0 kb PCR product was cloned into
Ase I–Hind III sites of pEGFP-N3 vector which we designated as
pH2KbΔα1α2 (Fig. 1A). The DNA fragment containing the leader, αl,
and α2 domains of Mamu-A⁎01 was ampliﬁed from genomic DNA of
Mamu-A⁎01 positive RM by PCR with primers 5-CCCTCGCGACAG-
GATGGCGGTCATGGCGC-3 and 5-CGCGGATCCCATTTGTCTCCCCTCC-3.
The 1.1 kb PCR product was cloned into Nru I–BamH I sites of
pH2KbΔα1α2 vector, and the completed plasmid was designated as
pH2KbMamu-A⁎01α1α2 (Fig. 1A). DNA sequence of all constructs was
conﬁrmed by standard automated DNA sequencing methods at the
City of Hope Core Sequencing Facility.
Production of Tg mice
A 3.4 kb Sal I–Not I chimeric monkey-mouse DNA fragment
containing the murine H-2Kb promoter, the leader, αl, and α2
domains of rhesus macaque Mamu-A⁎01 and the α3, transmembrane,
and cytoplasmic domains of murine H-2Kb was excised from
pH2KbMamu-A⁎01α1α2 (Fig. 1A) and puriﬁed by sucrose density
gradient fractionation, and injected into the pronuclei of fertilized
eggs from C57BL/6 H-2KbDb double MHC knockout (DKO) mice
according to established protocols (Mann and McMahon, 1993). The
microinjected eggs were transferred surgically to the uteri of 0.5 day-
post-coitus pseudo-pregnant recipient female mice (Mann, 1993). Tg
mouse founder lines were established by PCR detection of a 300 bp
genomic DNA fragment using the Mamu-A⁎01 speciﬁc primers
5-CCCCCACGGACGGCCCGCGTCG-3 and 5-CCGTCGTAGGCGTACTGTT-
CAT-3. Heterozygous Tg mice from a founder line designated Mamu-
A⁎01/Kb Tg mice line #4 (Fig. 2A) was selected for these studies. Cell
surface expression of Mamu-A⁎01 was detected in spleen cells by
staining with mAb W6/32 and analyzing by FACS immediately, or
following overnight culture in RPMI-10% FBS with 15 ng/ml murine
IFN-γ (PeproTech, Rocky Hill, NJ). All studies involving live animals
were conducted following review and approval of all protocols by the
City of Hope Institutional Animal Use and Care Committee, and in
accordance with all applicable guidelines.
Generation of recombinant vaccinia virus (VV)
The SIVmac239 Gag–Pol genes were ampliﬁed using primers:
5-TAAGAATGCGGCCGCGAGATGGGCGTGAGAAACTCC-3 and 5-
GACGTCGACCTATGCCACCTCTCTAGCC-3 from plasmid pSHIV-89.6 5′
(NIH AIDS Research and Reference Reagent Program). The resulting
4.4 kb DNA was cloned into pSC11-GFP using Not I and Sal I sites.
pSC11-GFP is a modiﬁed pSC11 vector in which the β-galactosidase
gene is replaced with the GFP gene (Chakrabarti et al., 1985) (kind gift
of Dr. Bernard Moss, LVD, NIAID, NIH). The SIVGag–Pol recombinant
vaccinia virus (rVV-SIVGag–Pol) was generated by transfecting the
plasmid into WR strain VV-infected Hu TK- cells. rVV-SIVGag–Pol
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cence microscope (Olympus, Tokyo, Japan) and simultaneously
selected with 0.1 mg/ml bromodeoxyuridine (Sigma-Aldrich, St
Louis, MO) for 5 rounds. The expression of SIV Gag protein was
detected from cell lysates prepared from rVV-SIVGag–Pol infected Hu
TK− cells by Western Blot analysis with anti-p27 MAb (NIH AIDS
Research and Reference Reagent Program).
Immunization of Mamu-A⁎01/Kb Tg mice with rVV-SIVGag–Pol and in
vitro stimulation (IVS) of spleen T lymphocytes
8 to 12 week old (N varies, see ﬁgure legends) mice (Tg line 4)
were i.p. injected with 2×107 PFU (plaque forming units) rVV-
SIVGag–Pol using a 1 ml syringe in a volume of 100 μL of PBS. After
14 days, the mice were killed, spleens were aseptically removed and
splenocyte suspensions were produced by teasing the spleen through
a sterile nylon mesh. RMA-S/Mamu-A⁎01/Kb as antigen-presenting
cells (APC) were loaded with 100 μM of the SIV Gag or Pol peptides for
3 h in a 37 °C and 5% CO2 incubator with occasional shaking. The IVS
was initiated by co-culture of 106 irradiated (5000 rad, Isomedix
Model 19 Gammator; Nuclear Canada, Parsippany, NJ) peptide-loaded
RMA-S/Mamu-A⁎01/Kb cells with splenocytes (3×106) from VV-
infected or control mice for 7 days in 2 ml medium containing 10% T-
Stim Culture Supplement (BD Biosciences, San Diego, CA).
Intracellular cytokine staining (ICC)
A total of 1×106 cells from 7 day IVS spleen cell cultures were
incubated at 37 °C for 1 h with 1 to 10 μM SIV peptides, or a mock
stimulation without peptide. Cells were then treated with 10 μg of
brefeldin A per ml to inhibit protein trafﬁcking and incubated
overnight at 37 °C. Cells were then washed twice with PBS plus 0.1%
BSA (Bovine Serum Albumin) and stained with FITC-conjugated CD8
MAb. After ﬁxation and permeabilization with the Cytoﬁx/Cytoperm
Plus Kit (BD Biosciences) according to the manufacturer's protocol,
cells were washed twice and then incubated with Allophycocyanin-
conjugated antibody to IFN-γ (BD Biosciences), and analyzed by FACS
on a two laser-6 color FACS-Canto™ (BD-Immunocytometry systems,
San Jose, CA). The number of double-positive cells is expressed as a
percentage of the CD8+ T-cell population.
Peptide vaccine immunization and in vivo VV challenge assay
Groups of Mamu-A⁎01 Tg female mice (8- to 12-weeks) were
immunized twice in a two week period on days 0 and 14 by a
combined s.c. at the base of the tail and i.p. approach with various
amounts of peptide vaccine plus 25 μg synthetic oligodeoxynucleotide
(ODN) 7909 with CpG motifs in a ﬁnal volume of 100 μl saline as
previously described. Seven days after the second immunization, the
mice were challenged i.p. with 1×107 PFU of rVV-SIVGag–Pol or rVV-
GFP. Five days post-challenge, mice were sacriﬁced and both ovaries
were removed. Following homogenization and three rounds of freeze–
thaw, ovary lysates (total volume was about 10 μl per ovary) were
assayed for VV titer by a modiﬁcation of a standard approach. The titer
of VV in ovary lysates was determined by plating serial 10-fold
dilutions on duplicate six-well plates of CV-1 cells (∼106 cells per
well). Following overnight incubation, monolayers were immuno-
stained with mAb to VV as primary, and an HRP-conjugate as
secondary, and plaques were counted (Wang et al., 2008).
Synthetic peptides
Individual nonamer and fusion vaccine peptides were prepared by
the standard solid phase Fmoc procedure using Symphony Peptide
Synthesizer (Protein Technologies, Inc., Tucson, AZ). Peptides were
puriﬁed by standard high performance liquid chromatographymethods using Agilent 1200 series (Agilent Technologies, Santa
Clara, CA), and molecular weight of peptides was conﬁrmed by matrix
assisted laser desorption/ionization (MALDI; Kratos, Chestnut Ridge,
NY) as previously described (La Rosa et al., 2002). The complete
SIVmac239 Gag and Pol (15-mer) peptides sets were obtained from
the NIH AIDS Research and Reference Reagent Program.
Statistical analysis
Results of challenge studies shown in Fig. 6B were analyzed using
theWilcoxon rank-sum test. All P-values were calculated as two sided,
with signiﬁcance deﬁned as Pb0.05. The statistical package Systat
12™ (Cranes Software Int. Ltd) was used for all calculations.
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